CRIS Current Research Information System

GUIDI, SANDRA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.790
AS - Asia 3.334
EU - Europa 2.355
AF - Africa 300
SA - Sud America 155
OC - Oceania 4
Continente sconosciuto - Info sul continente non disponibili 2
Totale 9.940
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.729
SG - Singapore 1.073
VN - Vietnam 815
IT - Italia 789
CN - Cina 777
GB - Regno Unito 409
DE - Germania 312
HK - Hong Kong 211
SE - Svezia 168
FR - Francia 121
IN - India 112
NL - Olanda 106
BR - Brasile 103
TG - Togo 84
CI - Costa d'Avorio 83
BD - Bangladesh 80
RU - Federazione Russa 74
IE - Irlanda 68
UA - Ucraina 65
ZA - Sudafrica 59
KR - Corea 56
JP - Giappone 53
FI - Finlandia 50
SC - Seychelles 37
CH - Svizzera 36
CA - Canada 35
BG - Bulgaria 34
PH - Filippine 31
JO - Giordania 29
EE - Estonia 24
BE - Belgio 22
TH - Thailandia 20
AR - Argentina 19
AT - Austria 18
TR - Turchia 17
NG - Nigeria 14
MX - Messico 13
GR - Grecia 11
IQ - Iraq 11
PL - Polonia 11
EC - Ecuador 10
ES - Italia 10
ID - Indonesia 8
TW - Taiwan 8
IR - Iran 7
JM - Giamaica 7
LT - Lituania 7
CL - Cile 6
KE - Kenya 6
SA - Arabia Saudita 6
CO - Colombia 5
AU - Australia 4
MY - Malesia 4
PK - Pakistan 4
PY - Paraguay 4
DZ - Algeria 3
ET - Etiopia 3
HR - Croazia 3
MA - Marocco 3
RO - Romania 3
UY - Uruguay 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AE - Emirati Arabi Uniti 2
AL - Albania 2
HU - Ungheria 2
MD - Moldavia 2
NP - Nepal 2
PE - Perù 2
SK - Slovacchia (Repubblica Slovacca) 2
SY - Repubblica araba siriana 2
UZ - Uzbekistan 2
VE - Venezuela 2
AO - Angola 1
BO - Bolivia 1
CG - Congo 1
CR - Costa Rica 1
CY - Cipro 1
CZ - Repubblica Ceca 1
DK - Danimarca 1
EG - Egitto 1
GA - Gabon 1
GP - Guadalupe 1
GT - Guatemala 1
LB - Libano 1
LV - Lettonia 1
NO - Norvegia 1
OM - Oman 1
PR - Porto Rico 1
PS - Palestinian Territory 1
PT - Portogallo 1
RE - Reunion 1
SD - Sudan 1
SI - Slovenia 1
SN - Senegal 1
SV - El Salvador 1
TN - Tunisia 1
TT - Trinidad e Tobago 1
Totale 9.940
Salva come PNG Salva come JPEG
Città #
Singapore 742
Ashburn 380
Southend 352
Fairfield 348
Chandler 338
Bologna 280
Santa Clara 225
Hanoi 196
Hong Kong 194
Ho Chi Minh City 190
San Jose 182
Houston 169
Seattle 160
Wilmington 158
Woodbridge 143
Ann Arbor 136
Hefei 125
Cambridge 118
Beijing 106
Princeton 92
Lomé 84
Abidjan 83
Dong Ket 78
Boardman 76
Dublin 68
Frankfurt am Main 63
Los Angeles 56
New York 48
Lauterbourg 46
Council Bluffs 44
Dallas 43
Falls Church 42
Seoul 42
Turin 42
Milan 41
Tokyo 41
Helsinki 39
Buffalo 37
Redmond 35
Jacksonville 34
Sofia 34
Westminster 34
Bern 30
Nanjing 30
Padova 29
Amman 28
Da Nang 26
San Diego 26
Munich 25
Rome 25
Haiphong 24
Johannesburg 24
Berlin 22
Brussels 21
Rimini 20
Shenyang 20
Guangzhou 19
Shanghai 19
Tianjin 18
Amsterdam 16
Chicago 16
Jinan 16
Florence 15
Hebei 15
The Dalles 15
Redondo Beach 14
Abeokuta 12
Bengaluru 12
Hải Dương 12
Orem 12
Wuhan 12
Changsha 11
Nanchang 11
Phoenix 11
Redwood City 11
Saint Petersburg 11
Toronto 11
Trento 11
Vienna 11
Zhengzhou 11
Bolzano 10
Castel Maggiore 10
Des Moines 10
London 10
Ha Long 9
Naples 9
Dearborn 8
Manila 8
Meldola 8
Montreal 8
Qingdao 8
São Paulo 8
Taizhou 8
Bangkok 7
Biên Hòa 7
Brooklyn 7
Bắc Ninh 7
Monmouth Junction 7
Mülheim 7
Ninh Bình 7
Totale 6.579
Salva come PNG Salva come JPEG
Nome #
Neonatal therapy with clenbuterol and salmeterol restores spinogenesis and dendritic complexity in the dentate gyrus of the Ts65Dn model of Down syndrome 308
A flavonoid agonist of the TrkB receptor for BDNF improves hippocampal neurogenesis and hippocampus-dependent memory in the Ts65Dn mouse model of DS 304
Treatment with the flavonoid 7,8-Dihydroxyflavone: a promising strategy for a constellation of body and brain disorders 271
Impaired brain mitochondrial bioenergetics in the ts65dn mouse model of down syndrome is restored by neonatal treatment with the polyphenol 7,8-dihydroxyflavone 257
Timing of Treatment with the Flavonoid 7,8-DHF Critically Impacts on Its Effects on Learning and Memory in the Ts65Dn Mouse 252
Obstructive sleep apneas naturally occur in mice during REM sleep and are highly prevalent in a mouse model of Down syndrome 239
Abnormal development of the inferior temporal region in fetuses with Down Syndrome 237
Early appearance of developmental alterations in the dendritic tree of the hippocampal granule cells in the Ts65Dn model of Down syndrome 228
Lithium Restores Age Related Olfactory Impairment in the Ts65Dn Mouse Model of Down Syndrome 226
Age-related impairment of olfactory bulb neurogenesis in the Ts65Dn mouse model of Down syndrome 220
Epigallocatechin gallate: A useful therapy for cognitive disability in Down syndrome? 218
Early appearance of dendritic alterations in neocortical pyramidal neurons of the Ts65Dn model of Down syndrome 217
Early Pharmacotherapy with Fluoxetine Rescues Dendritic Pathology in the Ts65Dn Mouse Model of Down Syndrome 214
Neonatal treatment with cyclosporine A restores neurogenesis and spinogenesis in the Ts65Dn model of Down syndrome 211
Long-term effect of neonatal inhibition of APP gamma-secretase on hippocampal development in the Ts65Dn mouse model of Down syndrome 204
Neuroanatomical Alterations in Higher-Order Thalamic Nuclei of Fetuses With Down Syndrome 202
Postnatal neurogenesis in the dentate gyrus of the guinea pig 198
APP-dependent up-regulation of Ptch1 underlies proliferation impairment of neural precursors in Down syndrome. 198
Increased hippocampal epigenetic age in the Ts65Dn mouse model of Down Syndrome 193
Inhibition of APP gamma-secretase restores Sonic Hedgehog signaling and neurogenesis in the Ts65Dn mouse model of Down syndrome 184
Early Pharmacotherapy Restores Neurogenesis and Cognitive Performance in the Ts65Dn Mouse Model for Down Syndrome 183
The flavonoid 7,8-DHF fosters prenatal brain proliferation potency in a mouse model of Down syndrome 182
Subicular hypotrophy in fetuses with Down syndrome and in the Ts65Dn model of Down syndrome. 180
Reversal of neurodevelopmental impairment and cognitive enhancement by pharmacological intervention with the polyphenol polydatin in a Down syndrome model 179
Sex differences in the stereological parameters of the hippocampal dentate gyrus of the guinea pig before puberty 177
Neuroanatomical alterations and synaptic plasticity impairment in the perirhinal cortex of the Ts65Dn mouse model of Down syndrome 177
Sex differences in the hilar mossy cells of the guinea-pig before puberty. 176
Pharmacotherapy with Fluoxetine Restores Functional Connectivity from the Dentate Gyrus to Field CA3 in the Ts65Dn Mouse Model of Down Syndrome 170
Early-occurring proliferation defects in peripheral tissues of the Ts65Dn mouse model of Down syndrome are associated with patched1 over expression 169
Impact of environmental enrichment on neurogenesis in the dentate gyrus during the early postnatal period. 169
Timing of therapies for downsyndrome: The sooner, the better 163
Prenatal pharmacotherapy rescues brain development in a Down's syndrome mouse model. 162
Cellularity Defects Are Not Ubiquitous in the Brains of Fetuses With Down Syndrome 157
Treatment with corn oil improves neurogenesis and cognitive performance in the Ts65Dn mouse model of Down syndrome. 155
Widespread proliferation impairment and hypocellularity in the cerebellum of fetuses with Down syndrome. 151
Short- and long-term effects of neonatal pharmacotherapy with epigallocatechin-3-gallate on hippocampal development in the Ts65Dn mouse model of Down syndrome 151
Changes in hippocampal morphology and neuroplasticity induced by adolescent THC treatment are associated with cognitive impairment in adulthood 147
Is it possible to improve neurodevelopmental abnormalities in Down syndrome? 142
Neonatal isolation impairs neurogenesis in the dentate gyrus of the guinea pig. 138
Postnatal neurogenesis in the hippocampal dentate gyrus and subventricular zone of the Goettingen minipig. 136
Dendritic phenotype and proliferation potency in the hippocampal dentate gyrus of the Ts66Yah model of Down syndrome 135
Fisiologia gastrointestinale 135
null 130
Targeting APP/AICD in Down syndrome 130
Neurogenesis impairment and increased cell death reduce total neuron number in the hippocampal region of fetuses with Down syndrome 126
Neurogenesis impairment: An early developmental defect in Down syndrome 125
Epigallocatechin-3-gallate: Linking the neurogenesis, hippocampus, and Down syndrome 119
Lithium restores neurogenesis in the subventricular zone of the Ts65Dn mouse, a model for Down sindrome 117
null 100
Long-term effects of neonatal treatment with fluoxetine on cognitive performance in Ts65Dn mice. 100
null 97
null 83
Sex differences in the hippocampal dentate gyrus of the guinea-pig before puberty 78
“Analisi dell’espressione genica in ippocampi di topi Ts65Dn sottoposti a trattamento adolescenziale con il BDNF-mimetico 7,8 diidrossiflavone” 73
“Administration of the BDNF mimetic 7,8-Dihydroxyflavone during adolescence rescues neuron maturation and improves hippocampus- dependent memory in the Ts65Dn mouse model of Down syndrome”. 65
“Il trattamento adolescenziale con il BDNF mimetico 7,8-diidrossiflavone influenza la metilazione del DNA nell'ippocampo del modello Ts65Dn di sindrome di Down” 63
“Effects of 7,8-dihydroxyflavone treatment on DNA methylation profiles of adolescent Ts65Dn mice hippocampus” 59
Effects of early environment on pyramidal neuron morphology in field CA1 of the guinea-pig 54
“Trattamento adolescenziale con il BDNF mimetico 7,8- diidrossiflavone: una strategia utile per migliorare lo sviluppo della fascia dentata ippocampica nel modello Ts65Dn di sindrome di Down”. 53
“Early pharmacotherapies for the rescue of intellectual disability in Down syndrome” 49
“Trattamento neonatale con astaxantina veicolata tramite nanoparticelle: effetti sullo sviluppo ippocampale e sullo stress ossidativo nel modello murino Ts65D” 49
“Adolescence represents an important window of opportunity for the rescue of dendritic pathology with a BDNF mimetic in a mouse model of Down syndrome” 48
Sex differences in the hilar mossy cells of the guinea-pig before puberty 48
“Is it possible to prevent or counteract Alzheimer’s disease in Down syndrome with molecules with antioxidant and anti-inflammatory properties?” 48
“Il trattamento con il polifenolo Polidatina migliora lo sviluppo cerebrale e la memoria ippocampo-dipendente nel topo Ts65Dn, modello di sindrome di Down” 47
Nitric oxide regulates cGMP-dependent cAMP-responsive element binding protein phosphorylation and Bcl-2 expression in cerebellar neurons: Implication for a survival role of nitric oxide 46
“La somministrazione neonatale di astaxantina tramite nanoparticelle ha un effetto proproliferativo nel modello murino Ts65Dn” 46
“Effects of neonatal treatment with astaxanthin-loaded stealth lipid nanoparticles on hippocampal neurogenesis in the Ts65Dn mouse model of Down syndrome” 45
“Neonatal treatment with astaxanthin-loaded stealth lipid nanoparticles fosters hippocampal neurogenesis in a mouse model of Down syndrome” 40
Totale 10.153
Salva come PNG Salva come JPEG
Categoria #
all - tutte 27.430
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 27.430
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022847 49 40 50 38 95 54 64 51 37 53 164 152
2022/20231.231 107 232 65 169 70 99 44 59 187 12 91 96
2023/2024343 23 62 19 40 22 68 3 8 4 25 40 29
2024/20251.479 94 112 107 119 269 74 128 71 28 120 91 266
2025/20263.927 322 261 246 292 417 328 366 183 835 293 227 157
2026/202733 33 0 0 0 0 0 0 0 0 0 0 0
Totale 10.153